Namenda (memantine) may provide a small benefit in thinking, daily function, behavior, and overall status for some people with moderate-to-severe Alzheimer's dementia. Its main risks include dizziness, headache, confusion, and constipation, while suitable candidates also need an allergy and kidney-function review. Namenda is an NMDA-receptor antagonist, a medicine that changes activity at a type of brain-cell receptor. It is not a general treatment for every form or stage of dementia.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What benefits can families realistically expect?
- Who may be a candidate?
- Can Namenda be used with donepezil?
- What are the main risks?
- What should be reviewed before treatment?
What benefits can families realistically expect?
The evidence suggests modest symptom management, not a dramatic recovery. A Cochrane review covering up to 14 studies and about 3,700 participants found high-certainty evidence of small benefits in cognition, daily activities, behavior, and overall clinical status in moderate-to-severe Alzheimer's disease. These benefits occurred with or without a cholinesterase inhibitor, such as donepezil according to the Cochrane review. One 28-week U.S.
trial included 252 people with moderate-to-severe probable Alzheimer's. Participants receiving memantine had significantly better cognition and day-to-day function scores than those receiving placebo. "Better than placebo" does not necessarily mean that a person visibly improves. It can mean that abilities decline more slowly or remain stronger than they otherwise might have. Families should therefore set concrete expectations around tasks that matter, such as dressing, eating, conversation, or participation in routine activities.
Who may be a candidate?
The key requirements are the type and stage of dementia. The FDA labeling described in DailyMed covers moderate-to-severe dementia of the Alzheimer's type—not mild Alzheimer's disease or dementia from every cause according to the February 2024 prescribing information.
The Cochrane review found probable no benefit for mild Alzheimer's disease. That finding does not support starting memantine early simply because someone has received an Alzheimer's diagnosis. Before considering treatment, ask the prescriber to clarify: These checks matter because "having dementia" alone does not establish that someone fits the population in which memantine has shown benefit.
- Whether the diagnosis is Alzheimer's dementia or another cause
- Whether the condition is moderate or severe
- What abilities or symptoms the medicine is expected to affect
- How the family and clinician will judge whether treatment is worthwhile
Can Namenda be used with donepezil?
Memantine may be used alone or added to a cholinesterase inhibitor in appropriate patients. In a 24-week trial of 404 people already taking donepezil, those who added memantine had statistically better cognition and activities-of-daily-living scores than those who added a placebo. Both groups generally deteriorated, which reinforces that the expected advantage is limited rather than restorative. NICE recommends memantine alone for severe Alzheimer's disease.
It also recommends it for moderate Alzheimer's when acetylcholinesterase inhibitors are contraindicated or not tolerated. For people already taking one of those medicines, NICE advises considering memantine in moderate disease and offering it in severe disease under guideline NG97. A person taking donepezil should not assume it must be replaced. The relevant discussion is whether adding memantine offers enough potential benefit to justify another medicine and its side effects.
What are the main risks?
In controlled trials, the most common adverse reactions occurring in at least 5% of memantine recipients—and more often than with placebo—were dizziness, headache, confusion, and constipation. Discontinuation because of adverse reactions occurred in 10.1% of memantine recipients and 11.5% of placebo recipients. Confusion deserves particular attention because a new medication effect may be mistaken for a change in the underlying dementia.
Families can record when a symptom began, whether it followed treatment changes, and how it affects daily activity before contacting the prescriber. Memantine should be avoided in anyone allergic to it. Prescribers must also account for kidney function and conditions that make urine more alkaline, because alkaline urine can reduce memantine elimination and increase drug levels.
What should be reviewed before treatment?
A focused medication appointment can establish whether the expected small benefit is meaningful for the person's circumstances. Bring an updated medicine list and information about the dementia diagnosis, current abilities, kidney problems, allergies, and recent changes in cognition or behavior. Ask the clinician to document a few observable treatment goals.
Those goals might involve maintaining a specific daily activity or reducing the pace of a measurable decline, rather than expecting the person to return to an earlier level of function. People with severe renal impairment require a reduced target dose of 5 mg twice daily. Do not change the dose without the prescriber who reviewed the person's kidney function and complete medication history.
